impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Case Reports

 

Capillary leak syndrome in a patient with cancer-associated anti-transcriptional intermediary factor 1γ dermatomyositis treated with rituximab

1, 2, 3, 4, 5, 6, 7

 

  1. Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy. biancalucia.palermo01@universitadipavia.it
  2. Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy.
  3. Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte (CHULN), Centro Académico de Medicina de Lisboa (CAML), Lisbon, ERN ReCONNET Full Member, and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisbon, Portugal.
  4. Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ERN ReCONNET Full Member.
  5. Anaesthesia and Intensive Care, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  6. Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy.
  7. Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy.

CER15367
2022 Vol.40, N°5 ,Suppl.134
PI 0118, PF 0120
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 35238769 [PubMed]

Received: 25/11/2021
Accepted : 09/02/2022
In Press: 22/02/2022
Published: 18/05/2022

Abstract

Capillary leak syndrome (CLS) is a rare condition characterised by increased capillary permeability, with subsequent hypoalbuminemia and hypotension, leading to an increased risk of shock and death. We present the case of a patient with anti-transcriptional intermediary factor 1γ dermatomyositis that developed CLS one week after starting treatment with rituximab and prophylactic co-trimoxazole. The patient was admitted to the Intensive Care Unit (ICU), recovered after treatment with intravenous immunoglobulin, albumin, and Ringer lactate, but died a month after the discharge due to a poorly differentiated hepatocarcinoma diagnosed in the ICU.

DOI: https://doi.org/10.55563/clinexprheumatol/j26b6o

Rheumatology Article